31 stories tagged #Novo Nordisk

  1. How a 1922 Rescue Mission Explains Ozempic’s $969 US vs. €59 German Price
    health

    How a 1922 Rescue Mission Explains Ozempic’s $969 US vs. €59 German Price

    The identical semaglutide pen costs sixteen times more in the US than in Germany. The price gap traces back to a Canadian discovery, a Danish foundation, and America's unique pharmacy-benefit system.

    last wk. 2 min read
  2. From Lizard Venom to National Phenomenon: How GLP-1 Drugs Reached One in Eight Americans
    health

    From Lizard Venom to National Phenomenon: How GLP-1 Drugs Reached One in Eight Americans

    A Bronx endocrinologist’s discovery in Gila monster saliva, initially rejected by the government, spawned a class of drugs now used by roughly one in eight U.S. adults for weight loss and diabetes.

    last wk. 2 min read
  3. Novo Nordisk Opens Affordable Access to Semaglutide Through Medicare GLP-1 Bridge
    health

    Novo Nordisk Opens Affordable Access to Semaglutide Through Medicare GLP-1 Bridge

    Novo Nordisk launches a nationwide Medicare program offering its FDA-approved semaglutide injection and pill for a fixed $50 monthly copay through 2027.

    last wk. 1 min read
  4. Health Canada Greenlights First Generic Semaglutide Injection for Weight Loss
    health

    Health Canada Greenlights First Generic Semaglutide Injection for Weight Loss

    Canada approves Apotex's Svemia, a generic Wegovy alternative, expanding affordable chronic weight management options following a reduced-calorie diet and exercise.

    last wk. 1 min read
  5. Medicare Launches Pilot Program for Weight-Loss Drugs Wegovy, Zepbound
    health

    Medicare Launches Pilot Program for Weight-Loss Drugs Wegovy, Zepbound

    A new Medicare bridge program will cover popular weight-loss medications like Wegovy and Zepbound for eligible older adults starting July 1st, with a $50 monthly copay.

    2w ago 1 min read
  6. UK Approves First Daily Oral GLP-1 Semaglutide for Obesity Treatment
    health

    UK Approves First Daily Oral GLP-1 Semaglutide for Obesity Treatment

    Novo Nordisk secures UK approval for daily oral semaglutide, offering a non-injectable alternative for obesity management with significant weight loss results in clinical trials.

    3w ago 1 min read
  7. Boehringer's Obesity Drug Shows Promising Weight Loss, Flagging Tolerability Concerns
    health

    Boehringer's Obesity Drug Shows Promising Weight Loss, Flagging Tolerability Concerns

    Boehringer Ingelheim releases detailed phase 3 obesity drug data: 16.6% weight loss, significant liver fat reduction, but tolerability issues spark investor sell-off.

    last mo. 1 min read
  8. Semaglutide Boosts Quality of Life in Diabetes and Kidney Disease Patients
    health

    Semaglutide Boosts Quality of Life in Diabetes and Kidney Disease Patients

    New FLOW trial data shows semaglutide improves daily functioning and well-being in adults with type 2 diabetes and chronic kidney disease.

    last mo. 1 min read